Platinum-based chemotherapy is a standard treatment for ovarian cancer, but its effectiveness can be limited in some cases.
A subgroup analysis hints that chemotherapy may be skipped after complete resection, but the finding needs further study.
SurvivorNet on MSN
'Mo-Rez,' a developing ovarian cancer drug, outperforms current standards with 60% response rates, offering first real hope in years
Early data show the cancer drug mocertatug rezetecan (Mo‑Rez) delivering response rates above 60% in patients with ovarian ...
Luke O’Neill told The Pat Kenny Show on Saturday, that new cancer treatments are extending patients lifespans.
Preclinical data show encouraging activity of azenosertib combinations in ADC-resistant TNBC, supporting the potential for pipeline expansion beyond ovarian cancer Real-world data demonstrate Cyclin ...
MedPage Today on MSN
High response rates in platinum-resistant ovarian cancer with immunotherapy agents
Also from SGO: p53 reactivator active in advanced gynecologic cancers, "perfect" score in ...
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company advancing cancer treatments, ...
Late-Phase Research Presented at Society of Gynecologic Oncology Annual Meeting FORT MYERS, Fla., April 13, 2026 /PRNewswire/ -- Late-phase clinical research conducted with participation from Florida ...
Dr. Alexander B. Olawaiye presented findings at the 2026 Society of Gynecologic Oncology Annual Meeting showing that adding ...
A study published April 10 in The Lancet reports that the anti-PD-1 immunotherapy pembrolizumab (brand name Keytruda) ...
SV-based ctDNA Monitoring in Metastatic Breast Cancer (mBC) ...
Low-grade serous ovarian cancer (LGSOC) is a rare type of ovarian cancer that's often slow-growing and hard to detect early and treat. It can start in your: Ovaries, where your pregnancy hormones and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results